FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri

August 24, 2023 -- The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Tyruko, like...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news